Local Open-Label Access Study For Patients Who Completed A1481244 Study In Brazil

Summary

The purpose of this study is to provide sildenafil therapy to patients who completed the A1481244 study for the treatment of PAH, and reside in Brazilian States where Revatio™ is not supplied by Health Secretary, and are judged by the Investigator to derive clinical benefit from continued treatment with Sildenafil. It will be supplied until patient gets access to Sildenafil through Brazilian State Health Secretary from where patient resides.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications